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to associate with class I molecules in TAP-negative cellsat Dallas
(Henderson et al., 1992; Wei and Cresswell, 1992). Cer-Dallas, Texas 75235
tain epitopes in the nonleader region of transmembrane
proteins are also reported to be presented in a TAP-
independent manner (Hammond et al., 1993, 1995; Lee
Summary et al., 1996). It is thought that leader peptides released
into the ER by the signal peptidase and some portion of
Qa-1b and its human homolog, HLA-E, predominantly ecto-domains of membrane proteins can be processed
bind leader peptides derived from other class I mole- by the inherent ER enzymatic machinery. The peptide-
cules. Their presentation is TAP-dependent and pro- trimming activity of the ER has been confirmed by its
teasome-independent. We demonstrate that Dd tar- ability to process truncated protein fragments targeted
geted to the cytosol does not generate the Qa-1b by leader sequences in TAP-negative cells (Elliott et
peptide epitope even in the presence of lactacystin. al., 1995). However, the presentation of other epitopes
Cells expressing herpes virus ICP-47 block the genera- embedded in secreted or membrane proteins is strictly
tion of this epitope, demonstrating that TAP functions TAP-dependent, indicating they are directed to the cyto-
in the transport of the peptide from cytosol to ER. This solic pathway (Hammond et al., 1995; Ferris et al., 1996;
reveals a pathway for antigen presentation of leader Bacik et al., 1997; Mosse et al., 1998). Two mechanisms
peptides that involves translocation of a protein to the have been shown to account for the cytosolic pro-
ER where its leader is cleaved followed by its release cessing of such proteins. First, certain epitopes derived
into the cytosol and transport back into the ER. Fur- from viral envelope proteins are generated from misdi-
ther, it ensures that Qa-1b expression mirrors the nor- rected cytosolic forms of molecules (Ferris et al., 1996).
mal expression of class Ia molecules. Second, some proteins are translocated from the ER
back to the cytosol for processing (Bacik et al., 1997;
Mosse et al., 1998).Introduction
It is commonly thought that the efficiency of the ER
to process intact proteins is limited (Snyder et al., 1994).MHC class I molecules present endogenous peptide
Some epitopes can only be successfully generated byfragments toCD81 T cells for screening of viral infections
the proteasome in the cytosol (Elliott et al., 1995; Mosseand malignant transformation (Heemelsand Ploegh,1995;
et al., 1998). However, it is uncertain whether or not thisYork and Rock, 1996). Cell surface class I molecules
is also the reason why some leader-derived peptidescan also interact with inhibitory receptors to regulate NK
are TAP-dependent. Examples of this group of epitopescells (Ljunggren and Karre, 1990; Lanier, 1997). Mature
were first demonstrated for a leader peptide presentedclass I molecules are heterotrimers containing a heavy
by murine class Ib molecule Qa-1b (Aldrich et al., 1994).chain, a b2 microglobulin (b2m) light chain, and a peptide
Further evidence indicates that a similar peptide derivedligand of usually 8±10 amino acids. Peptides are impor-
from LCMV glycoprotein, a model peptide epitope in-tant for the assembly and surface expression of theclass
serted into the leader of Db, and peptides derived fromI complexes. The association of peptides with newly
the leaders of HLA class I molecules and presented bysynthesized class Iheavy chains occurs in theendoplas-
HLA-E also require TAP for their presentation (Hombachmic reticulum (ER). There are at least two routes, the
et al., 1995; Uger and Barber, 1997; Braud et al., 1998a).cytosolic pathway and the translocon pathway, to allow
Qa-1b presents a nonamer peptide derived from theaccess of peptides to nascent class I molecules (How-
leader of class Ia molecules. Our previous studies haveard, 1995). The cytosolic pathway involves partial pro-
shown that this peptide complexed with Qa-1b can betein degradation in the cytosol and translocation of the
recognized by ab T cells and induce an alloreactiveresultant peptides into the ER via the transporter associ-
response (Lowen et al., 1993; Aldrich et al., 1994). Theated with antigen processing (TAP) (Neefjes et al., 1993;
possible physiological function of this presentation isShepherd et al., 1993). The major proteolytic activity in
indicated by the finding that HLA-E, the human homologthe cytosol is attributed to a multimeric, multicatalytic
of Qa-1, binds a similar set of leader-derived peptidesprotease complex, the proteasome (Goldbergand Rock,
and interacts with CD94/NKG2 NK cell receptors (Bor-1992). While cytosolic proteins are processed only
rego et al., 1998; Braud et al., 1998b). In an effort tothrough the cytosolic pathway, complexity is found in
further characterize the processing mechanism of thisthe processing of secretory proteins. Epitopes derived
leader peptide, we generated a panel of Dd mutant mole-from this group of proteins can be processed through
cules containing single amino acid replacements in their
leaders. Our results show that some mutations can af-
fect or even abrogate the leader function as well as§To whom correspondence should be addressed (e-mail: iforma
processing of the Qa-1b binding epitope. Using a virus-@mednet.swmed.edu).
‖ These authors contributed equally to this work. derived TAP inhibitor (Fruh et al., 1995; Hill et al., 1995),
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to a Gly. The mutant constructs were inserted into re-Table 1. Protein Sequence of Dd Leader Segment and Mutants





Surface Expression and Maturation of Dd MoleculesM5 MGAMAPRTLLLLLAAALGGTQTRA
Bearing Mutations in Their Leader Sequences
The sequence of the Dd leader and leader mutants is listed above.
To test whether the mutations introduced into the DdThe peptide bound by Qa-1b is underlined. Mutated residues are
leader have any effect on its ability to deliver the Ddshown in bold for M1, M2, M3, and M5.
molecules into the secretory pathway, cell surface ex-
pression of Dd was analyzed by flow cytometry. Cells
infected with rVV encoding wild-type Dd, M2, or M3 ex-
press comparable levels of surface Dd as detected bywe demonstrate that it is the transporter function of TAP
that is absolutely required for the surface presentation 2 Dd-specific monoclonal antibodies 34-2-12 (anti-a3
domain) and 34-5-8s (anti-a1 and a2 domains) (Figureof this epitope. In spite of this, targeting Dd directly to
the cytosol rather than the ER prevents its generation. 1A). This indicates that removal of the positively charged
residue from the N-terminal region (M2) does not ad-
versely affect the leader's function. Efficient surface ex-
Results pression of another mutant, M3, which bears a conser-
vative Ala→Val substitution, is not surprising, because
Strategy and Construction of Dd Mutants the same substitution is found in a naturally occurring
We have previously shown that Qa-1b predominantly leader sequence (Dk). Cells infected with rVV-M1 fail
binds a single nonamer peptide derived from the leader to express detectable surface Dd, indicating that the
segment of D-region class Ia molecules (Aldrich et al., disruption of thehydrophobicity of the core region prob-
1994). D-region leader segments are comprised of 24 ably resulted in a dysfunctional leader. Mutating the Pro
amino acids and are similar to leader segments in other residue in the signal peptide cleavage region (M5) also
proteins. The N-terminal region has a charged residue significantly decreased the surface Dd expression, sug-
(Arg) at P (position)7, a central hydrophobic core, and gesting this residue may be involved in signal peptidase
a polar carboxy-terminal domain. The junction between recognition and cleavage. The biosynthesis and matura-
the C terminus of the leader and start of the Dd protein tion of Dd mutants M2, M3, and M5 were also examined
is an Ala/Gly bond that is presumably cleaved by signal by pulse-chase and immunoprecipitation followed by
peptidase. The nonamer peptide bound by Qa-1b com- endo-H treatment (Figures 1B and 1C). Over a 2 hr chase
prises amino acids 3±11 (AMAPRTLLL). Although this period, the synthesis and rate of acquisition of endo-H
peptide is located in the leader segment, it is TAP- resistance was similar for all constructs. However, much
dependent for its expression and does not require pro- fewer Dd molecules can be detected from rVV-M5-
teasome activity (Bai and Forman, 1997). In these experi- infected cells by the conformational antibody 34-5-8s,
ments, we wished to determine whether this epitope suggesting that alteration of this proline results in less
arose as a result of its misdirected generation in the efficient delivery of Dd into the secretory pathway and
cytosol rather than transport to the ER followed by tran- is consistent with surface staining data.
sit to the cytosol. Our approach was to alter the structure
of the leader segment both within and outside of the
antigenic epitope. To accomplish this, we constructed Biosynthesis of Dd Bearing a Mutation
in the Hydrophobic Core of thea series of mutants in the leader segment of the class
Ia molecule, Dd (Table 1). To affect the leader segment's Leader Segment
Although Dd molecules exported into the ER can belocalization, we altered its hydrophobic core such that
the P13 Leu is changed to a positively charged amino precipitated by either 34-2-12 or 34-5-8s, neither of them
can detect a Dd molecule produced by rVV-M1 (data notacid, Arg (M1). This substitution should prevent efficient
binding of the signal recognition particle to the leader shown). Since a protein natively directed to the ER may
be misfolded when synthesized in the cytosol, a poly-segment, thus localizing such molecules to the cyto-
plasm (Izard and Kendall, 1994). Mutants M2 and M3 clonal serum (216-F) against nonconformed murine
class I molecules was used to test the expression ofrepresent changes in the Qa-1b binding epitope itself.
Thus, in M2, Arg at position 7 (P5 of the peptide) is the M1 molecule. Figure 2A shows that 2 bands can be
identified in the lysate of HeLa cells infected with rVV-mutated to a Cys, which allows us to study the effect
of charge in the N region of the leader on the processing M1 after 15-min labeling. In contrast to the wild-type Dd
molecule that is glycosylated and sensitive to theand presentation of this epitope. M3 has its Ala at posi-
tion 5 changed to a Val. This change should produce a endo-H treatment, neither of these bands are shifted
after endo-H digestion. When compared with the degly-peptide with a Val at P3, which is knownto berecognized
by some but not all anti-Qa-1b CTL clones (Aldrich et cosylated Dd molecule, the higher molecular weight
band migrates slower, while the predominant lower oneal., 1994). Because Pro located 4±5 residues upstream
from the signal sequence cleavage site has been shown migrates faster. Toclarify the relationship between these
two bands, we performed a short pulse-chase experi-to have a positive effect on the rate of processing (Shen
et al., 1991), the M5 mutant had the P19 Pro changed ment. As shown in Figure 2B, only the higher molecular
Leader Peptide Processing for Qa-1b
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Figure 2. Expression of Dd Molecules in Cells Infected with rVV-Dd
or rVV-M1
(A) HeLa cells were infected with rVV-Ova, rVV-Dd, or rVV-M1 for 2.5
hr and then labeled with 0.2 mCi/ml [35S]methionine for 15 min. Dd
molecules were immunoprecipitated with antiserum 216-F. (B) Cells
were infected as in (A) and pulse labeled for 1 min. 6 3 106 cells
were either lysed immediately or chased for 10 min. Antiserum 216-F
was used to precipitate Dd molecules.
(C) HeLa cells infected with indicated viruses were labeled with
[35S]methioine for 30 min and immunoprecipitation was performed
with a Dd-reactive anti-cytoplasmic tail serum. Immunoprecipitates
were incubated at 378C overnight with endo-H or N-glycanase
(PNGase F). Samples were analyzed by 11% SDS-PAGE.
the clipping site is different from the native signal pepti-
dase cleavage site.
Figure 1. Surface Expression, Biosynthesis, and Maturation of Dd Ability of Mutant Dd Proteins to Generate the Qa-1b
Molecules Bearing Mutations in Their Leaders
Binding Peptide, as Detected by Specific CTL
HeLa cells were infected with rVV encoding either wild-type Dd or
L cells transfected with Qa-1b (L-Qa-1b) were infectedDd mutants at an MOI of 20. (A) At the end of the 5 hr infection, cells
with rVV constructs and tested for their ability to bewere stained with either 34-2-12 or 34-5-8s and mean fluoresence
lysed by anti-Qa-1b-specific CTL. Clone 3C9 is specificwas measured by flow cytometry. (B) Cells infected for 2.5 hr were
pulse labeled and chased for indicated time periods. Dd molecules for Qa-1b molecules that have bound the leader-derived
were precipitated with MAb 34-5-8s and digested with endo-H. (C) peptide (Aldrich et al., 1994). This clone recognizes
The gel from (B) was quantitated on a PhosphorImager and the L-Qa-1b target cells infected with rVV-Dd while the same
fraction of endo-H-resistant form of total Dd molecules was plotted.
cells either uninfected or infected with VV-wt are not
recognized (Figure 3A). Target cells infected with rVV
containing mutants M2 and M3 are not recognized byweight band is seen following a 1-min pulse. After a 10-
min chase, almost all this band disappears; meanwhile, clone 3C9. This result is expected since these mutant
genes encode leaders that have changed the epitope.the lower band becomes prominent. This indicates that
a full-length M1 molecule containing the mutant leader Thus, M2 has a Cys rather than Arg at P5 of the peptide,
and M3 has a Val rather than Ala at P3. This result issegment is synthesized in the cytosol. This precursor
molecule is very short-lived and rapidly truncated into consistent with our findings that clone 3C9 does not
recognize Qa-1b-expressing target cells pulsed with thea smaller product. This truncation likely occurs at the N
terminal end of the molecule because an antiserum corresponding synthetic mutant peptides (Aldrich et al.,
1994; data not shown).cross-reactive to the cytoplasmic tail of Dd can still rec-
ognize the truncated product after prolonged labeling Different results were obtained using the two mutants
that did not alter the epitope directly but did alter Dd(Figure 2C). The final product is even smaller than
N-glycanase (PNGase)-treated Dd (Figure 2C), indicating cellular localization and/or the quantity of the mature
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Clone 5D2 is specific for Qa-1b and recognizes this
molecule when it presents either the D-region leader
peptide or a variant that has an Ala↔Val interchange
at P3 (AMVPRTLLL). Thus, unlike 3C9, which cannot
recognize Qa-1b on cells from the H-2k haplotype, clone
5D2 can because Dk is the only D allele that has a Val
rather than Ala at this position in its leader. Accordingly,
clone 5D2 displays moderate levels of lysis against
L-Qa-1b cells because L cells are Dk positive (Figure
4A). Infection with rVV-Dd enhances lysis, as expected.
Unlike what was noted with clone 3C9, infection with
rVV-M3 also enhances 5D2-mediated target cell lysis
because it encodes the epitope with a Val at P3, identical
to that encoded by Dk. The weak ability of rVV-M5 to
up-regulate the killing was barely visible here because
of the high level of endogenous peptide supply and the
counter-effect of virus infection. Interestingly, infection
with rVV-M2 decreased 5D2 recognition,suggesting that
a T cell unrecognizable peptide (AMAPCTLLL) derived
from this mutant may compete for Qa-1b binding with
the endogenous Dk-derived peptide.
We tested 5D2 against HeLa-Qa-1b cells (Figure 4B).
Here, the background lysis is lower than that seen using
L-Qa-1b target cells. Infection with rVV-Dd led to lysis by
Figure 3. Lysis of Qa-1b-Expressing Cells by CTL Clone 3C9, Spe- this clone, and even greater recognition was noted when
cific for AMAPRTLLL Presented by Qa-1b the cells were infected with rVV-M3. At high E:T ratios,
(A) Untransfected L cells or L cells expressing Qa-1b were infected rVV-M5 showed moderate ability to enhance the killing.
with rVV encoding Dd or Dd-mutants M1, 2, 3, or 5. Closed square, The lysis of L-Qa-1b targets by clone 5D2 was not en-
L cells 1 rVV-Dd; closed triangle, L-Qa-1b; closed upsidedown trian-
hanced by infection with rVV-M1 nor did clone 5D2 rec-gle, L-Qa-1b 1 rVV-Dd; closed diamond, L-Qa-1b 1 rVV-M1; closed
ognize rVV-M1-infected HeLa-Qa-1b cells.circle, L-Qa-1b 1 rVV-M2; open square, L-Qa-1b 1 rVV-M3; open
triangle, L-Qa-1b 1 rVV-M5.
(B) Untransfected HeLa cells or HeLa cells expressing a Qa-1b/Db
hybrid molecule were infected with rVV as in (A). Closed triangle, Requirement of the Peptide Transport Function
HeLa-Qa-1b; closed upsidedown triangle, HeLa-Qa-1b 1 rVV-Dd; of TAP for the Presentation of the
closed diamond, HeLa-Qa-1b 1 rVV-M1; closed circle, HeLa- Leader-Derived Epitope
Qa-1b 1 rVV-M2; open square, HeLa-Qa-1b 1 rVV-M3; open triangle,
In human cells, class I molecules associate with TAPHeLa-Qa-1b 1 rVV-M5; open upsidedown triangle, HeLa; open circle,
through a bridge molecule tapasin in the ER (SadasivianHeLa-Qa-1b 1 VV-wt.
et al., 1996). Although the murine homolog of tapasin(C and D) L-Qa-1b cells were uninfected or infected with rVVs for
2.5 hr in the absence (C) or presence (D) of 80 mM lactacystin. The has not been identified, the association of class I and
CTL assay was performed in the presence of 3 mM BFA. Closed TAP has also been demonstrated in murine cells (Suh
triangle, L-Qa-1b; closed upsidedown triangle, L-Qa-1b 1 rVV-Dd; et al., 1994). This association is believed to facilitate
closed diamond, L-Qa-1b 1 rVV-M1; open circle, L-Qa-1b 1 VV-wt.
peptide loading. In the tapasin-deficient cell line .220,
class I molecules are not able to associate with TAP, and
the assembly and surface expression of some alleles ofmolecules. Thus, rVV-M1, which encodes Dd that is syn-
thesized and localized to the cytosol, did not produce class I molecules are impaired (Grandea et al., 1995). It
is possible that the TAP-dependence of the leader epi-the Qa-1b binding peptide that could be recognized by
clone 3C9. In contrast, rVV-M5 was capable of sensitiz- tope for Qa-1b presentation reflects the requirement of
TAP-facilited peptide loading rather than peptide trans-ing target cells for 3C9 lysis, although at a diminished
level. port from cytosol to ER. We used herpes simplex virus
protein ICP-47 to test this possibility. ICP-47 has beenWe also tested clone 3C9 against HeLa cells that were
transfected with a hybrid gene that encodes the a1/a2 shown to bind TAP from the cytosolic side to block
peptide transport without interfering with the classdomains of Qa-1b (HeLa-Qa-1b); the rest of the molecule
is derived from Db (Cotterill et al., 1997). Even though I±TAP association in the ER (Fruh et al., 1995; Hill et al.,
1995). Since ICP-47 only acts on human TAP moleculesthe Db leader in this construct encodes the epitope,
Qa-1b expression and its recognition by the anti-Qa-1b (Ahn et al., 1996; Tomazin et al., 1996), a human lympho-
blastoid (C1R) cell line stably transfected with Qa-1bCTL clones on these cells is very low. This result is also
illustrated in the data shown in Figure 3B where lysis of (C1R-Qa-1b) was used in this experiment.
C1R-Qa-1b cells are not recognized by CTL clone 3C9HeLa-Qa-1b by 3C9 is minimal. Infection of HeLa-Qa-1b
cells with rVV-Dd leads to strong recognition of these unless pulsed with the synthetic peptide (Figure 5).
rVV-Dd infection renders these cells sensitive to lysis bycells. Again, very weak killing was seen with rVV-M2 or
rVV-M3-infected targets. Similar to the result seen with clone 3C9. However, coinfection with rVV-ICP-47 mark-
edly suppresses the killing. This inhibition is likely dueL-Qa-1b cells, infection with rVV-M5 enhanced 3C9 rec-
ognition but less potently compared with rVV-Dd. to the block of peptide supply, because the lysis can be
Leader Peptide Processing for Qa-1b
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Figure 4. Lysis of Qa-1b-Expressing Cells by
CTL Clone 5D2, Specific for AMAPRTLLL or
AMVPRTLLL Presented by Qa-1b
(A) Untransfected L cells or L cells expressing
Qa-1b were infected with rVV encoding Dd or
Dd-mutants M1, 2, 3, or 5. Closed square, L
cells 1 VV-Dd; closed triangle, L-Qa-1b; closed
upsidedown triangle, L-Qa-1b 1 rVV-Dd;
closed diamond, L-Qa-1b 1 rVV-M1; closed
circle, L-Qa-1b 1 rVV-M2; open square,
L-Qa-1b 1 rVV-M3; open triangle, L-Qa-1b 1
rVV-M5.
(B) Untransfected HeLa cells or HeLa cells
expressing a Qa-1b/Db hybrid molecule were
infected with rVV as in (A). Closed square,
HeLa cells 1 VV-Dd; closed triangle, HeLa-Qa-1b; closed upsidedown triangle, HeLa-Qa-1b 1 rVV-Dd; closed diamond, HeLa-Qa-1b 1 rVV-M1;
closed circle, HeLa-Qa-1b 1 rVV-M2; open square, HeLa-Qa-1b 1 rVV-M3; open triangle, HeLa-Qa-1b 1 rVV-M5; open upsidedown triangle,
HeLa; open circle, HeLa-Qa-1b 1 VV-wt.
restored by incubating the target cells with the synthetic surface expression is closely correlated with the avail-
ability of this single set of peptides (Braud et al., 1998a).peptide. Cell surface expression of the virus-derived Dd
molecules was monitored as an internal control for the The functional relevance behind this phenomenon has
recently been implied by the finding that HLA-E canaction of ICP-47. Flow cytometry analysis showed ICP-
47 also inhibits the surface expression of this class Ia interact with CD94/NKG2 family NK receptors (Borrego
et al., 1998; Braud et al., 1998b).molecule (data not shown). The effect observed is not
due to any alteration of Dd synthesis. Metabolic labeling Previous studies have shown that almost all cell sur-
face Qa-1b molecules in lymphoblasts are occupied byand immunoprecipitation of Dd show that the same
amount of Dd was synthesized in the presence of ICP- the single peptide derived from the leader of D-end class
Ia molecules (DeCloux et al., 1997). In this paper, we47, but most of the molecules were retained in the ER
during the chase (data not shown). Therefore, by in- have characterized the processing mechanism of this
peptide. By introducing a positively charged residue intoterfering with the transporter function of TAP, ICP-47
can blockthe surface presentation of the leader peptide, the hydrophobic core of the Dd leader, the protein's
confirming that this peptide does come from thecytosol.
Effect of Lactacystin on Anti-Qa-1b CTL Recognition
of Cells Infected with rVV-M1
It is possible that the reason that cells infected with rVV-
M1 are not recognized is that the proteasome cleaves
the protein within the epitope. Since the proteasome is
not required for the generation of the peptide (Bai and
Forman, 1997), we tested whetheraddition of the protea-
some inhibitor lactacystin might protect it from possible
destructive cleavage (Figures 3C and 3D). L-Qa-1b cells
were infected with either VV-wt, rVV-Dd, or -M1 either in
the presence or absence of lactacystin. After a 2.5 hr
incubation, the cells were cultured in the presence of
Brefeldin A and tested with 3C9 CTL. This clone showed
enhanced lysis of L-Qa-1b cells infected with rVV-Dd but
not -M1 (Figure 3C). The addition of lactacystin had no
effect on inhibiting this lysis or revealing lysis against
cells infected with rVV-M1 (Figure 3D).
Discussion
Figure 5. Inhibition of the Presentation of the Leader-Derived Epi-
In contrast to the initial findings that leader-derived pep- tope by ICP-47
tides could be eluted from MHC class I molecules of C1R-Qa-1b cells were mock infected, infected with VV-wt or rVV-Dd
TAP-negative cells, several recent studies described the alone, or coinfected with rVV-Dd plus VV-wt or rVV-ICP-47 for 2.5
hr. The sensitization of target cells for lysis by CTL clone 3C9 wasTAP-dependent presentation of leader-derived peptides
tested with a 4 hr CTL assay. When indicated, targets were pulsed(Aldrich et al., 1994; Hombach et al., 1995; Uger and
with 100 ng of the synthetic nonamer peptide (AMAPRTLLL). ClosedBarber, 1997; Braud et al., 1998a). Among these, the
diamond, C1R-Qa-1b; open diamond, C1R-Qa-1b 1 peptide; C1R-presentation of peptides derived from the leaders of
Qa-1b cells infected with: closed square, VV-wt; closed triangle, rVV-
other class I molecules by the class Ib molecule Qa-1 Dd; closed upsidedown triangle, rVV-Dd 1 VV-wt; open upsidedown
and its human homolog HLA-E is particularly interesting. triangle, rVV-Dd 1 VV-wt 1 peptide; closed circle, rVV-Dd 1 rVV-
ICP-47; open circle, rVV-Dd 1 rVV-ICP-47 1 peptide.Both molecules are ubiquitously expressed, but their
Immunity
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normal transport was completely blocked, as indicated
by the absence of its surface expression and failure to
be glycosylated. Our data suggest this mutant molecule
is rapidly clipped at its N terminal end where the intact
Qa-1b binding epitope resides. However, a peptide-spe-
cific CTL assay showed that the Qa-1b epitope was un-
able to be generated from this cytosolic form of the
molecule in cells with functional TAP. Since the trun-
cated product is smaller than the deglycosylated Dd
molecule, it seems that the clipping site is not at the
mutated residue. Whether or not this mutation is in-
volved in the cleavage in some other ways is not known.
Nevertheless, it is possible that native Dd molecules that
fail to cotranslationally engage to the translocon un-
dergo similar processing. Our results indicate that these
misdirected molecules arenot thesource of thenaturally
processed peptide, and the liberation of the leader seg-
ment by the signal peptidase is required for thesuccess-
ful processing of this epitope. These features distinguish
Figure 6. Model of the Processing Pathways for TAP-Dependentthe cytosolic processing of leader-derived from non-
and TAP-Independent Leader Peptidesleader-derived epitopes. For epitopes in the internal re-
(A) The leader segment is cleaved by signal peptidase (sp) andgion of ER-destined proteins, cytoplasmic targeting en-
released into the lumen of the ER. The precise epitope is generated
hances their processing and this processing is mostly by an ER peptidase and binds to class I molecules in TAP-negative
proteasome-dependent (Tobery and Siliciano, 1997; cells. (B) Some cleaved leader segments are either directly released
Mosse et al., 1998). We previously demonstrated that the into the cytosol (route 1) or shuttled back to the cytosol from the
ER via an unknown transporter (route 2). Such epitopes require TAPprocessing of the Qa-1b binding epitope is proteasome-
to be presented by class I molecules. a, ribosome; b, translocon;independent (Bai and Forman, 1997). The reason why
c, leader segment; d, class I epitope; e, class I heavy chain; f, b2m;this epitope cannot be processed after the primary clip-
g, tapasin; h, TAP; i, unknown back transporter.
ping is unknown. Evidence for destruction of cryptic
epitopes by the proteasome has been shown (Nieder-
in the prokaryotic leaders because of their formylatedmann et al., 1995; Yellen-Shaw et al., 1997; Luckey et al.,
N-terminal Met but not required for eukaryotes because1998). However, using the proteasome-specific inhibitor
of the existing positive charge carried by the protonizedlactacystin, we found that the processing of the epitope
terminal amino group (von Heijne, 1985). Recent studiesfrom the cytosolic form of Dd could not be rescued.
showed that some leader peptides could undergo fur-Recent studies suggest that proteases other than the
ther processing that is sensitive to cyclosporin A follow-proteasome exist in the cytosol (Cerundolo et al., 1997;
ing the initial cleavage (Lyko et al., 1995; Martoglio et al.,Vinitsky et al., 1997; Glas et al., 1998; Luckey et al., 1998).
1997). An intriguing question is whether the N-terminalIt will be interesting toknow whether these proteasesare
charged residue determines the trafficking of the finallyresponsible for the destruction of this epitope.
processed leader segment. Since the positively chargedWhile we cannot formally show that signal peptidase
Arg is located within the T cell epitope and the CTLis required for generation of the Qa-1b binding epitope,
clone recognizing the peptide with a residue other thanthe analysis of another mutant (M5) supports this notion.
Arg is not available, we cannot decide this issue at pres-Here, we mutated the Pro at P19 to a Gly, and observed
ent. However, inhibition of the CTL recognition by theboth a decrease in the export and surface expression
mutant M2 suggests the corresponding nonamer pep-of Dd as well as the generation of the Qa-1b binding
tide may be generated and able to compete the Qa-1epitope. The Pro residue at the boundary between the
binding with endogenous peptides. This is supportedhydrophobic core and the carboxy-terminal region has
by our binding studies that a peptide with a Cys at P5been shown to enhance signal peptidase recognition
can bind Qa-1b with a similar affinity to that of the wild-and cleavage of leader segments (Shen et al., 1991). A
type nonamer peptide (data not shown).possible explanation of this effect is that the proline
According to the results of other groups and the evi-residue prevents the extension of the helical structure
dence provided in this study, there are at least twofrom the core region to the cleavage region and creates
groups of leader-derived peptides that are processeda turn or loop structure that is favored by the signal
differently. Currently no consensus based on the struc-peptidase (Yamamoto et al., 1990).
ture of the leader or the location of the epitope in theOur data indicate that the N-terminal positively
leader for either group has been defined. While TAP-charged residue is not required for the leader function.
independent leader peptides are likely released andThe positive charge is thought to be important for the
trimmed in the ER (Figure 6A), how and why some leaderinteraction with the negatively charged surface of the
peptides enter the cytosolic pathway have not beenmembrane (Inouye et al., 1982). However, statistical
resolved. One possibility is peptide recycling from thestudies of the leader sequences in the database demon-
ER to the cytosol as described in an in vitro systemstrated a lesser occurrence of the positively charged
(Roelse et al., 1994) (Figure 6B, route 2). Another expla-residue in eukaryotic leaders (Nielsen et al., 1997). It
was hypothesized that the positive charge is crucial nation is that some leader peptides are further released
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Yewdell, NIAID, NIH, Bethesda, MD) at the SalI and BglII sites. Re-into the cytosol without exposure to the ER lumen as
combinant vaccinia virus (rVV) was generated as previously de-suggested by Lyko et al. (1995) (Figure 6B, route 1). We
scribed (Mackett et al., 1985). rVVs expressing ICP-47 and oval-favor the latter hypothesis because (1) the leader epitope
bumin (Ova) were provided by Dr. J. W. Yewdell (NIAID, NIH,
is proteasome-independent (Bai and Forman, 1997) and Bethesda, MD).
(2) peptide-trimming activities in the ER have been con-
firmed by numerous studies (Henderson et al., 1992; Flow Cytometry
Wei and Cresswell, 1992; Hammond et al., 1993, 1995; HeLa cells were infected with rVV at an MOI of 40. After 5 hr of
infection, cells were stained sequentially with 34-2-12 or 34-5-8sElliott et al., 1995; Lee et al., 1996; Snyder et al., 1997).
and a goat anti-mouse IgG-FITC (Capell, Durham, NC) and analyzedTogether, the requirement of both signal peptide recog-
on a Becton-Dickinson FACScan flow cytometer (Beckton Dickin-nition and transit in the cytosol represents a unique
son, San Jose, CA).
pathway of peptide processing.
Qa-1 and HLA-E bind similar peptides and the interac- Immunoprecipitation
tion of the latter with CD94/NKG2 receptors on NK cells HeLa cells were infected with rVV at an MOI of 20 for 2.5 hr. Cells
leads to the inhibition of their cytolytic activity (Borrego were then starved in methioine-free medium for 30 min and labeled
with 0.2 mCi/ml (0.5 mCi/ml for 1-min pulse) Tran35S label (ICN,et al., 1998; Braud et al., 1998b). Here, we demonstrate
irvine, CA) for 15±30 min. When indicated, labeled cells were chasedthat the expression of Qa-1 and presumably HLA-E is
with complete medium containing excess methionine for variouscontrolled by the generation of an epitope that requires
times. 4 3 106 cells (6 3 106 cells for 1-min pulse) were lysed onER to cytosol back to ER trafficking. This ensures that
ice with 0.5 ml lysis buffer (1% NP-40, 10 mM Tris-HCl [pH 7.5], 150
NK signaling through HLA-E (and Qa-1?) parallels the mM NaCl, 5 mM EDTA, 5 mM iodoacetamide, 1 mM PMSF, and 0.1
normal cell surface expression of class Ia molecules. trypsin inhibitor U/ml aprotinin) for 30 min. The postnuclear superna-
tants were immunoprecipitated by the sequential incubation with
Abs and protein-A Sepharose beads (Pierce, Rockford, IL). Endo-H
Experimental Procedures or N-glycanase (Boehringer Mannheim, Indianapolis, IN) digestion
was performed as described in manufacturer instructions. Samples
Reagents were separated by SDS-PAGE and the gels were visualized with a
Lactacystin was purchased from Dr. E. J. Corey (Harvard University, PhosphorImager (Molecular Dynamics, Seal Beach, CA).
Cambridge, MA). Brefeldin A (BFA) was obtained from Sigma Chemi-
cal Co. (St. Louis, MO). The synthesis of the Qa-1b binding peptide
CTL Assay(AMAPRTLLL) was described previously (Aldrich et al., 1994).
Virus infection was performed as described above and was allowed
to proceed for 2.5 hr before 51Cr labeling. The standard 51Cr release
Cell Lines assay and the determination of percent lysis have been described
Qa-1b-specific CTL clones 3C9 and 5D2 and the C1R-derived Qa-1b (Aldrich et al., 1994). In some experiments, target cells were incu-
transfectant have been previously described (Aldrich et al., 1994). bated with lactacystin at 80 mM for 30 min prior to virus infection
The Qa-1b-transfected mouse L cell line was a kind gift from Dr. M. and throughout the first 2.5 hr of infection. BFA was then added at
Soloski (John Hopkins University, Baltimore, MD). HeLa-Qa-1b cells a concentration of 5 mg/ml for 30 min, and the remainder of the
were generated by transfecting HeLa cells with a Qa-1b/Db con- assay was carried out in the presence of 3 mg/ml BFA.
struct (Cotterill et al., 1997). L, Tk143, and HeLa cells were obtained
from American Type Culture Collection (Rockville, MD). L, C1R, and
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